• Minicabecera4

News

Histocell has now completed the first round of financing included in its strategic plan 2015-2020. Investment needs reach € 4 million, which will be allocated mainly to complete the development of 3 medical devices and phase I/IIa clinical trial of 2 cellular medicines.

Continue...

Bio Europe ParisFrom 9th to 11th March Histocell participated in one of the most important biotechnological partnerings in Europe which (this year) took place in Paris. More than 20 meetings of great interest were held with companies based in Europe, USA, South Korea and Southeast Asian countries, in order to present Reoxcare and make commercialisation agreements. Reoxcare is an innovative dressing with antioxidant properties to treat wounds of all kinds, especially those which are hard to heal.
Reoxcare is almost ready to be commercialised, and this has allowed the product to be widely welcomed by the companies contacted. The presentation of Wharton Gel Complex was also a strong point in the meetings held: the new cosmetic ingredient was highly valued by several companies.

 


KuwaitHistocell received last 27th of february the visit of some members of the Government of Kuwait, including the Science and Education Minister Bader Al-Issa, who had the opportunity to know Histocell's facilities at the Bizkaia Tecnology Park after a couple of days in Bilbao.

Not only did they bring with them a great view of the city and its modernism, but also the importance of the work carried out in research at Histocell and the latest innovations of the company in the development of Regenerative Medicine products.

Histocell has recently finished the development of Reoxcare, an active wound dressing for hard-to-heal skin wounds. Its unique design, based on the antioxidant properties of its compenents, has been patented internationally. Reoxcare has been successfully tested in different types of wounds, included pressure ulcers and traumatic and surgical wounds.

Histocell plans to launch the product to the market by the end of 2015, once the CE mark allowing to commercialise it in Europe is obtained.

 


ReoxcareReoxcare is an innovative wound dressing that promotes natural healing in hard-to-heal skin wounds. Histocell and Luqa have signed a licensing agreement for the product in the People's Republic of China, Hong Kong and Macau.

After several years of research, Histocell has finished the development of its new product Reoxcare for wound healing. Reoxcare is an active wound dressing for hard-to-heal skin wounds. Its unique design, based on the antioxidant properties of its compenents, has been patented internationally. Reoxcare has been successfully tested in different types of wounds, included pressure ulcers and traumatic and surgical wounds.

Histocell plans to launch the product to the market by the end of 2015, once the CE mark allowing to commercialise it in Europe is obtained.

Continue...